Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK630.00.
An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.
Novo Nordisk A/S reported a 22% growth in operating profit in Danish kroner and 20% at constant exchange rates (CER) to DKK 38.8 billion in the first three months of 2025.
Sales in US Operations rose by 20% in Danish kroner and 17% at CER, while sales in International Operations grew by 18% in Danish kroner and 19% at CER in the same period.
Novo Nordisk A/S also experienced a 21% growth in Danish kroner in sales within Diabetes and Obesity care, primarily attributed to the Obesity care growth of 67% in Danish kroner to DKK 18.4 billion and GLP-1 diabetes sales growth of 13% in Danish kroner.
Novo Nordisk A/S is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.
Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center